---
title: "UroGen Pharma to Present at Guggenheim Securities Emerging Outlook Biotech Summit"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274816846.md"
datetime: "2026-02-04T13:00:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274816846.md)
  - [en](https://longbridge.com/en/news/274816846.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274816846.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274816846.md) | [English](https://longbridge.com/en/news/274816846.md)


# UroGen Pharma to Present at Guggenheim Securities Emerging Outlook Biotech Summit

UroGen Pharma Ltd. will present at the Guggenheim Securities Emerging Outlook: Biotech Summit on February 12, 2026, at 2:30 PM ET in New York, NY. The event will feature a fireside chat and 1x1 investor meetings, with a webcast available on UroGen’s corporate website. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9648319-en) on February 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [Urogen Pharma (URGN.US)](https://longbridge.com/zh-HK/quote/URGN.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)

## 相關資訊與研究

- [Clene 2025 net loss narrows as expenses fall](https://longbridge.com/zh-HK/news/278880252.md)
- [Prelude Therapeutics reports $99.5 mln net loss for 2025](https://longbridge.com/zh-HK/news/278542482.md)
- [Century Therapeutics 2025 net loss narrows beating estimates](https://longbridge.com/zh-HK/news/278880556.md)
- [Capricor Theraputics Q4 revenue falls to zero, net loss widens](https://longbridge.com/zh-HK/news/278939139.md)
- [Incannex Healthcare Prices $10 Mln Potential Offering Of Shares And Warrants; Stock Down](https://longbridge.com/zh-HK/news/278896600.md)